Kymera | Investor Presentation Deck | 60 slides · page 31 of 60
The footer highlights the safety profile: no serious adverse events (SAEs), no drug-related infections, and no dose interruptions or discontinuations.
Pitch deck · appendix_data · analyze_data · balanced density
Slide locked Sign in to view
Slide schematic 3/3
paragraph 1/1 table 1/1 title 1/1
Components 3
paragraph data headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.